Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378196 | 0.89 | ADRB2 (0.49) | ADRB2KDM4EL3MBTL1AOC3LMNA | |
| Hydrochloric Acid SCHEMBL4378868 | 0.88 | ADRB2 (0.48) | ADRB2KDM4EL3MBTL1AOC3LMNA | |
| SCHEMBL5848458 | 0.84 | AOC3 (0.46) | ADRB2KDM4EL3MBTL1AOC3LMNA | |
| SCHEMBL11742820 | 0.84 | AOC3 (0.46) | ADRB2KDM4EL3MBTL1AOC3LMNA | |
| SCHEMBL30140834 | 0.81 | ADRB2 (0.48) | ADRB2KDM4EL3MBTL1LMNAADRB1 | |
| SCHEMBL6320068 | 0.81 | KDM4E (0.73) | ADRB2KDM4EL3MBTL1AOC3LMNA | |
| SCHEMBL1626455 | 0.81 | KDM4E (0.73) | ADRB2KDM4EL3MBTL1AOC3LMNA | |
| SCHEMBL12186418 | 0.81 | ADRB3 (0.57) | ADRB2LMNAADRB3ADRB1 | |
| SCHEMBL19352867 | 0.81 | SMN1; SMN2 (0.50) | ADRB2KDM4EL3MBTL1AOC3LMNA | |
| SCHEMBL1690587 | 0.81 | POLB (0.49) | ADRB2LMNAADRB3ADRB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273883-B2 | Method for producing optically active 2-arylpiperazine derivative | KANEKA CORPORATION (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100087643-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | KANEKA CORPORATION (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2119709-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | Kaneka Corporation (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087643-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | CYP2W1, AGPS, DHPS | ADRB2 424/4885KDM4E 2876/4885L3MBTL1 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.